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Abstract
Background Building research capacity of European Society of Clinical Pharmacy (ESCP) members aligns to the organisa-
tion’s aim of advancing research. Objective To determine members’ aspirations and needs in research training and practice, 
and to explore ways in which ESCP could provide support. Setting ESCP’s international membership. Method Cross-sectional 
survey of members in 2018, followed by focus groups with samples of respondents attending an ESCP symposium. Survey 
items were: research activities; interests, experience and confidence; and Likert statements on research conduct. Principal 
component analysis (PCA) clustering of Likert statements from a previous study was used, with scores for each component 
calculated. Focus groups discussed barriers to research and how ESCP could provide support. Data analysis involved collating 
and comparing all themes. Main outcome measures Research interest, experience and confidence; attitudinal items; barri-
ers to research; ESCP support. Results The response rate was 16.7% (83/499), with 89.2% (n = 74) involved in research and 
79.5% (n = 66) publishing research in the preceding 2 years. While overwhelmingly positive, responses were more positive 
for research interest than experience or confidence. PCA component scores (support/opportunities, motivation/outcomes, 
and roles/characteristics) were positive. Thirteen members participated in focus groups, identifying barriers of: insufficient 
collaboration; lack of knowledge, skills, training; unsupportive environment; insufficient time; and limited resources. ESCP 
could support through mentorship, collaboration, education and funding. Conclusion Study participants were highly active, 
interested, experienced, confident and positive regarding research. There is an opportunity for ESCP to harness these activi-
ties and provide support in the form of mentoring, education and training, and facilitating collaboration.
Keywords Barriers · Clinical pharmacy · Enablers · European Society of Clinical Pharmacy · Research
Impacts on practice
• There is an opportunity for ESCP to harness the research 
activities, interest, experience, confidence and generally 
positive views to create greater impact for patients, pro-
fessionals, organisations and society across Europe and 
beyond.
• ESCP as an organisation can provide support in the form 
of mentoring, education and training, focusing most on 
those form non-academic settings.
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Introduction
Pharmacy practice is continually evolving, with pharma-
cists providing enhanced services involving direct patient 
care, such as general practice-based activities, non-medi-
cal prescribing, and specialist roles in ambulatory, second-
ary and tertiary care [1–4]. Consequently, the application 
of evidence-based practice (EBP), the integration of best 
available evidence with practitioners’ clinical expertise 
and patients’ values [5], is highly relevant. Awareness of, 
and participation in, research could facilitate adoption of 
EBP within current and emerging roles.
Professional organisations and regulatory bodies are 
placing increasing emphasis on participation in research. 
For example, the International Pharmaceutical Federation 
(FIP) emphasises the need for pharmacists to take on sig-
nificant responsibilities in research in order to contribute 
to improvements in global health by advancing drug dis-
covery and development, clinical practice and education 
[6].
However, limited published research exists on pharma-
cists’ current involvement in research and their future needs. 
Current available literature is mostly based in either the UK 
or non-European countries [7, 8]. In addition, there is a lack 
of consistent application of how research involvement or 
engagement has been defined and adopted. The existing 
published literature, albeit limited, suggests that barri-
ers to participation and involvement are often behavioural 
in nature. For example, barriers include a lack of knowl-
edge, skills and self-motivation. There is therefore a need 
to incorporate behaviour change theories or frameworks 
in undertaking future research in the area. Incorporation 
of behaviour change theory permits the identification of 
possible theoretical mechanisms of behaviour change lead-
ing to the development of targeted intervention(s) [9]. The 
Theoretical Domains Framework (TDF) includes constructs 
from 33 behaviour change theories, described in 14 domains 
(i.e. the determinants of behaviour) of: knowledge; skills; 
social/professional role and identity; beliefs about capabili-
ties; optimism; beliefs about consequences; reinforcement; 
intentions; goals; memory, attention and decision processes; 
environmental context and resources; social influences; emo-
tions; and behavioural regulation.
The use of the TDF has previously enabled assessment of 
associated barriers of pharmacists’ involvement in research, 
in diverse practice settings in Scotland [8]. Key barriers 
mapped to TDF domains of ‘knowledge’ (e.g. organization 
research priorities, training and funding opportunities), and 
‘environmental context and resources’ (e.g. research active 
environment, time, support). Study limitations included the 
low response rate and absence of a qualitative phase to allow 
in-depth exploration of survey findings.
The European Society of Clinical Pharmacy (ESCP) is 
a professional network of clinical pharmacists in Europe. 
Established in 1979, ESCP aims to ‘promote, support, 
implement and advance education, practice and research in 
clinical pharmacy in order to optimise outcomes for patients 
and society’ [10]. Building research capacity, defined as 
‘enhancing the abilities of individuals, organisations and 
systems to undertake and disseminate high quality research 
effectively and efficiently’ [11], aligns to this aim. There 
is an opportunity to engage with this network to identify 
the needs and future requirement of pharmacists in order to 
harness pharmacy practice research capacity and activities 
across Europe.
Aim of the study
Aims of the study were to determine ESCP members’ aspira-
tions and needs in relation to research training and practice 
and to explore ways in which ESCP could support members 
in meeting these needs.
Ethics approval
The ESCP General Committee approved the study; as par-
ticipants were members of an international organisation, 
there was no need for ethical review.
Method
Design
This was an explanatory, sequential mixed methods study 




All ESCP members were invited to participate, excluding 
members of the ESCP Research Committee (n = 8), giving 
a study population of 499.
Questionnaire development
The questionnaire was based on that used in Scotland [8], 
adapted for the ESCP context. Items were based on the 14 
domains of the TDF and the Transtheoretical Model of 
Behaviour Change [12]. Stages of change are ‘pre-con-
templation’ (not ready), ‘contemplation’ (getting ready), 
‘preparation’ (ready), ‘action’ and ‘maintenance’. In the 
demographics section, respondents classified themselves as 
1075International Journal of Clinical Pharmacy (2020) 42:1073–1087 
1 3
innovators, early adopters, early majority, late majority and 
laggards based on receptivity to change, using the wording 
described by Rogers [13].
The questionnaire was tested for face and content validity 
by the members of the ESCP Research Committee. Given 
the previous use of a similar questionnaire [8], no pilot stage 
was conducted. The questionnaire was developed in Bristol 
Online Survey© and tested for compatibility with platforms 
(PC, tablet, smartphone), browsers and internet filters. Ques-
tion types were a combination of closed and open questions 
to allow respondents to provide comments. Evidence-based 
strategies were employed to maximise the response rate [14], 
including: an information leaflet outlining the study aim and 
potential benefits; assuring anonymity; an attractive ques-
tionnaire; and two follow-up email reminders.
Data collection
During September 2018, ESCP members were sent an email 
from the ESCP International Office with a direct link to the 
information leaflet and questionnaire. Two email reminders 
were sent to all ESCP members at approximately 2-monthly 
intervals.
Analysis
The survey instrument generated data that were exported 
to Statistical Package for Social Sciences (SPSS Inc., Cary, 
NC version 25.0). Descriptive analysis was undertaken for: 
demographics; research activities; research interest, expe-
rience and confidence; views on research conduct; and 
readiness to participate in research and research training. 
Internal consistencies of responses on interest, experience 
and confidence were tested using Cronbach’s alpha, aiming 
for values ≥ 0.7 [15]. Total scores [median and interquartile 
range (IQR)] for each scale were obtained by assigning val-
ues (1 = no to 5 = very). Differences in total scores of inter-
est, experience and confidence were tested using Friedman’s 
two-way analysis of variance by ranks. Correlation between 
overall scores of interest/experience, interest/confidence and 
experience/confidence were assessed using Spearman’s rho. 
P values ≤ 0.05 were considered to be statistically signifi-
cant. Given the number of responses, it was not possible to 
conduct any inferential statistical analysis to investigate any 
differences between subgroups (e.g. age etc.)
While it was intended to use principal component anal-
ysis (PCA) to reduce the large number of TDF-related 
items to a smaller number of components [16], the num-
ber of responses proved insufficient. Consequently, the 
PCA components identified in the study in Scotland [8], 
were used to group the items into: support and opportu-
nities to be involved in research; motivation for and out-
comes of involvement in research; and individual roles and 
characteristics around involvement in research. Following 
determination of internal consistencies for each of the three 
components, total scores (median and interquartile range, 
IQR) were obtained by assigning scores of 1 (strongly disa-
gree) to 5 (strongly agree) to each of the Likert statement 
responses and each of these compared to the scale midpoint.
Summative content analysis was independently performed 
by two members of the research team on the responses to the 
open questions, looking for patterns, similarities and differ-
ences [17].
ESCP symposium focus group
Recruitment
The focus group discussion took place at the ESCP Sympo-
sium in October 2018. Those attending the symposium who 
had completed the questionnaire were invited to participate. 
The session was of 1-h duration and moderated by three 
ESCP Research Committee members.
Data generation and analysis
Participants were arranged into groups, with data generated 
in two separate stages. In Stage 1, each participant was asked 
to individually record the top three barriers to fulfilling their 
research aspirations. These were recorded on post-it notes, 
which were then arranged into thematic groupings on a 
flip chart by group members. In Stage 2, groups discussed 
how ESCP could facilitate their research aspirations, being 
cognisant of the limited resources of ESCP. Each group 
recorded the outcomes of their discussion on flip charts as 
in Stage 1. Data analysis was independently undertaken by 





Eighty-three responses were received, giving a response rate 
of 16.7%. Personal and practice demographics are shown in 
Table 1. Respondents were from a range of largely European 
countries, mainly Switzerland (13.3%, n = 11), Netherlands 
(10.8%, n = 9), Norway (7.2%, n = 6) and the UK (7.2%, 
n = 6). The majority had been ESCP members for ≤ 5 years 
(55.4%, n = 46), were aged < 50 years (71.1%, n = 59) and 
male (65.1%, n = 54). Just under half were working in 
academia (42.2%, n = 35), had worked > 15 years (47.0%, 
n = 39) and the majority were working full-time (81.9%, 
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Table 1  Personal and practice 




























 Albania, Croatia, Cyprus, Denmark, Estonia, ‘EU’, Ireland, Spain 9.6 (1 each)
 Asia 8.4 (7)
 Africa 1.2 (1)
Years member of ESCP






 > 30 2.4 (2)
Main practice setting
 Academia 42.2 (35)
 University hospital 22.9 (19)
 Non-university hospital 14.5 (12)
 Community pharmacy 7.2 (6)
 Industry 1.2 (1)
 Primary care medical practice 1.2 (1)
 Other 10.8 (9)
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n = 68). Respondents were highly qualified with more than 
half possessing a Ph.D. (68.7%, n = 57). In terms of receptiv-
ity to change, almost three quarters (72.3%, n = 70) classified 
themselves as innovators and early adopters.
Research involvement
Over the preceding 2  years, 89.2% (n = 74) had been 
involved in research, 51.8% (n = 43) as principal investi-
gator and 54.2% (n = 45) as co-investigator. The majority 
(79.5%, n = 66) had published research, 45.8% (n = 38) as 
corresponding author and 59.0% (n = 49) as co-author. Three 
quarters (74.7%, n = 62) had presented research at an inter-
national conference and around two-fifths (38.6%, n = 32) 
had supervised doctoral students.
Research interest, experience and confidence
Responses to items on interest, experience and confidence 
are reported in Table 2. The Cronbach’s alpha values for 
the items on interest, experience and confidence were 0.91, 
0.96 and 0.95 respectively, indicating internal reliability. 
The median summary score (range possible 16–80, scale 
mid-point 48; high scores positive) for research interest was 
68 (IQR 59–73), research experience 62 (IQR 53–70) and 
research confidence 64 (IQR 56–70). Summary scores for 
interest were significantly higher than confidence which 
were significantly higher than experience (χ2, P < 0.001). 
There were positive correlations between total scores for 
interest and experience, interest and confidence, and con-
fidence and experience (Spearman’s rho, P < 0.001), with 
those more interested also more experienced and confident. 
The most negative responses were for items on: interest in 
conducting a systematic review, 42.1% (n = 35) reported no/
little/some interest; experience in conducting a systematic 
review, 59.1% (n = 49) reported no/little/some experience; 
confidence in conducting a systematic review, 49.4% (n = 41) 
reported no/little/some confidence; and confidence in ana-
lysing and interpreting qualitative results, 47.0% (n = 39) 
reported no/little/some confidence.
Research involvement
Attitudinal statements were grouped into three components 
as per the previous study [8], labelled: support and oppor-
tunities to participate in research (Cronbach’s alpha 0.90); 
motivation for and outcomes of participation in research 
(Cronbach’s alpha 0.896); and individual roles and charac-
teristics around participation in research (Cronbach’s alpha 
0.82). Responses to items of these three components are 
given in Table 3.
Component 1: Support and opportunities to be involved 
in research
Respondents generally held positive views, with a median 
overall score of 70 (IQR 61–77), range possible 18–90 (mid-
point 54), with 85 representing the highest possible posi-
tive score. The statements with the highest levels of disa-
greement were for the statements, ‘I have sufficient time to 
participate in research’ (disagree/strongly disagree 34.9%, 
n = 29) and ‘I have access to all of the resources (e.g. sta-
tistical advice, software) I need to be involved in research’ 
(disagree/strongly disagree 24.1%, n = 20).
Table 1  (continued)
Demographic % (n)
 26–30 4.8 (4)











 Innovative with new ways of working (innovator) 55.4 (46)
 Serve as role model for others (early adopter) 16.9 (14)
 Think for some time before adopting new ways of working (early majority) 26.5 (22)
 Cautious, tend to change once most peers have done so (late majority) 0
 Resist new ways of working (laggard) 1.2 (1)
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Table 3  Responses to attitudinal items on aspects of research conduct (n = 83)
Statement Strongly agree % (n) Agree % (n) Unsure % (n) Disagree % (n) Strongly 
disagree % 
(n)
Component 1: Support and opportunities to be involved in research
I work within a research-supportive environment 26.5 (22) 44.6 (37) 15.7 (13) 12.0 (10) 1.2 (1)
I work within a research-active environment 30.1 (25) 38.6 (32) 14.5 (12) 14.5 (12) 2.4 (2)
I am fully aware of the research priorities for my organization 24.1 (20) 48.2 (40) 22.9 (19) 3.6 (3) 1.2 (1)
Being involved in research is/would be supported by my 
organisation
43.4 (36) 36.1 (30) 16.9 (14) 3.6 (3) 0
Being involved in research is/would be supported by my 
profession
41.0 (34) 43.4 (36) 14.5 (12) 1.2 (1) 0
Being involved in research is/would be supported by my line 
manager
36.1 (30) 38.6 (32) 18.1 (15) 4.8 (4) 2.4 (2)
Being involved in research is/would be supported by my peers 38.6 (32) 36.1 (30) 20.5 (17) 4.8 (4) 0
I am fully aware of training opportunities relating to research 19.3 (16) 43.4 (36) 31.3 (26) 4.8 (4) 1.2 (1)
I am fully aware of funding opportunities relating to research 8.4 (7) 36.1 (30) 42.2 (35) 12.0 (10) 1.2 (1)
I am fully aware of opportunities to be involved in research 24.1 (20) 54.2 (45) 19.3 (16) 0 2.4 (2)
I have clear goals for being involved in research 44.6 (37) 39.8 (33) 9.6 (8) 4.8 (4) 1.2 (1)
Other pharmacists I know influence me to be involved in 
research
22.9 (19) 44.6 (37) 15.7 (13) 15.7 (13) 1.2 (1)
Other health professionals I know influence me to be involved 
in research
22.9 (19) 48.2 (40) 16.9 (14) 10.8 (9) 1.2 (1)
I have sufficient time to participate in research 13.3 (11) 31.3 (26) 20.5 (17) 22.9 (19) 12.0 (10)
I have access to all of the resources (e.g. statistical advice, 
software) I need to be involved in research
20.5 (17) 30.1 (25) 25.3 (21) 21.7 (18) 2.4 (2)
There are opportunities for me to attend research talks and 
seminars
24.1 (20) 56.6 (47) 12.0 (10) 7.2 (6) 0
There are opportunities for me to attend national research 
conferences
32.5 (27) 47.0 (39) 15.7 (13) 4.8 (4) 0
There are opportunities for me to attend international research 
conferences
27.7 (23) 50.6 (42) 16.9 (14) 4.8 (4) 0
Component statistics, sum of allocating 1 (strongly disagree) to 5 (strongly agree)
Cronbach’s alpha 0.90




Component 2: Motivation for and outcomes of involvement in research
Being involved in research is/would be of benefit to my profes-
sion
77.1 (64) 21.7 (18) 1.2 (1) 0 0
Being involved in research is/would be of benefit to my career 57.8 (48) 31.3 (26) 6.0 (5) 3.6 (3) 1.2 (1)
Being involved in research is/would be of benefit to patients 53.0 (44) 36.1 (30) 9.6 (8) 0 0
Being involved in research is/would be of benefit to my organi-
sation
59.0 (49) 32.5 (27) 7.2 (6) 0 0
Being involved in research is/would be of benefit to my profes-
sional practice
63.9 (53) 30.1 (25) 4.8 (4) 0 0
I get/would get professional satisfaction from being involved 
in research
62.7 (52) 32.5 (27) 3.6 (3) 1.2 (1) 0
I am motivated to be involved in research 60.2 (50) 31.3 (26) 6.0 (5) 2.4 (2) 0
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Component 2: Motivation for and outcomes of involvement 
in research
Responses were very positive, with a median overall score of 
33 (IQR 29–35), range possible 7–35 (midpoint 21), with 35 
representing the highest possible positive score. The state-
ments with the highest levels of agreement were for the 
statements, ‘Being involved in research is/would be of ben-
efit to my profession’ (agree/strongly agree 98.8%, n = 82) 
and ‘I get/would get professional satisfaction from being 
involved in research’ (agree/strongly agree 95.1%, n = 79).
Component 3: Individual roles and characteristics 
around involvement in research
Respondents generally held very positive views, with a 
median overall score of 52 (IQR 47–56), range possible 
12–60 (midpoint 36), with 60 representing the highest possi-
ble positive score. The most negative response was for ‘I feel 
anxious about being involved in research’ (agree/strongly 
agree 20.5%, n = 17).
Readiness to be involved in research
In response to questions on readiness to be involved in 
research: 1.2% (n = 1) had never thought about being 
involved in research; 6.0% (n = 5) had thought about being 
involved but had taken no action; 3.6% (n = 3) had thought 
about being involved and discussed with others; 7.2% 
(n = 6) had been involved in research in the past but had no 
plans to be involved in the future; 10.8% (n = 9) had been 
involved in research in the past and had plans to be involved 
in the future; and 71.1% (n = 59) were currently involved in 
research.
Table 3  (continued)
Statement Strongly agree % (n) Agree % (n) Unsure % (n) Disagree % (n) Strongly 
disagree % 
(n)
Component statistics, sum of allocating 1 (strongly disagree) to 5 (strongly agree)
Cronbach’s alpha 0.86




Component 3: Individual roles and characteristics around involvement in research
*Only academics should be involved in research 2.4 (2) 2.4 (2) 2.4 (2) 43.4 (36) 48.2 (40)
Being involved in research is already part of my professional 
role
57.8 (48) 33.7 (28) 3.6 (3) 3.6 (3) 0
It is my professional duty to be involved in research 57.8 (48) 24.1 (20) 13.3 (11) 2.4 (2) 2.4 (2)
I have sufficient methodological knowledge to be involved in 
research
33.7 (28) 49.4 (41) 14.5 (12) 1.2 (1) 1.2 (1)
I am sufficiently skilled to be involved in research 43.4 (36) 44.6 (37) 10.8 (9) 1.2 (1) 0
I am able to determine my own research-related training needs 36.1 (30) 50.6 (42) 9.6 (8) 3.6 (3) 0
I am confident in my ability to participate in research 47.0 (39) 44.6 (37) 8.4 (7) 0 0
I am competent to be involved in research 47.0 (39) 44.6 (37) 8.4 (7) 0 0
*I feel anxious about being involved in research 6.0 (5) 14.5 (12) 12.0 (10) 41.0 (34) 25.3 (21)
I am enthusiastic about being involved in research 57.8 (48) 36.1 (30) 3.6 (3) 2.4 (2) 0
Being involved in research makes/would make me feel happy 48.2 (40) 39.8 (33) 12.0 (10) 0 0
I support others to be involved in research 57.8 (48) 36.1 (30) 6.0 (5) 0 0
*Negative statement, reverse scored
Component statistics, sum of allocating 1 (strongly disagree) to 5 (strongly agree)
Cronbach’s alpha 0.82




Responses do not all total 100% due to missing data
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In terms of research training: 6.0% (n = 5) had never 
thought about research training; 14.5% (n = 12) had thought 
about research training but had taken no action; 16.9% 
(n = 14) had thought about research training and discussed 
with others; 6.0% (n = 5) had a plan for their research train-
ing; 6.0% (n = 5) had enrolled for research training; and 
50.6% (n = 42) had undertaken research training.
Relating to the specific types of training: 9.6% (n = 8) 
were not interested in any training; 34.9% (n = 29) were 
interested in training but not leading to a formal univer-
sity qualification; 16.9% (n = 14) were interested in uni-
versity training at postgraduate certificate or postgraduate 
diploma levels; 4.8% (n = 4) were interested in university 
training at masters level; and 33.7% (n = 28) were inter-
ested in university training at doctoral level.
Content analysis of responses to open questions 
throughout the questionnaire identified several key 
themes. While many expressed a desire to be more 
involved in research generally, lack of resources such as 
time and funding were barriers,
Basically motivated, but at the moment I lack in 
time for proper research.
Dedicated time, time and time!
Funding is very limited for the research in my country.
Responses to how ESCP could support research involve-
ment generated several themes, outlined in Table 4.
ESCP symposium discussion group
Thirteen ESCP members participated in the focus group 
held during the symposium, representing Turkey (n = 3), 
France (n = 2), Qatar (n = 2), Switzerland (n = 2), Croatia 
(n = 1), Nigeria (n = 1), Sweden (n = 1), UK (n = 1).
Research findings are presented under two main head-
ings of barriers and expectations.
Barriers to research aspirations ESCP members
Barriers to the clinical pharmacy research aspirations of 
the participants were categorised into five key themes and 
associated subthemes, as shown in Table 5.
Expectations from ESCP
There were five key themes and associated subthemes for 
their expectations from ESCP, as shown in Table 6.
Discussion
ESCP member respondents were highly involved in research, 
interested, experienced and confident. Responses to all three 
PCA components were positive, with the most negative for 
items on sufficient time and access to resources. Participants 
of the qualitative phase identified a number of areas in which 
ESCP could support their research aspirations through men-
toring, supporting collaboration, and providing education 
and training.
Strengths to this research include the mixed methods 
approach and the use of a framework of behaviour change 
theories. The major limitation is the response rate, which 
was disappointing given that the study population com-
prised members of a professional network. There are there-
fore potential issues resulting from response bias with those 
responding potentially more interested and involved in 
research. It is notable that in excess of 40% of respondents 
were from an academic setting and 70% possessed a Ph.D. 
Further limitations include the potential lack of validity of 
self-reported data and social desirability bias. The quantita-
tive results may therefore lack generalisability and the quali-
tative findings transferability to all ESCP members and the 
population of pharmacists in Europe.
It is, however, clear that there is a cohort of highly 
research active ESCP members involved in leading, 
Table 4  Themes and illustrative quotes in relation to how ESCP could support research involvement
Theme Illustrative quotes
Support through education and training Offer relative, interactive and certified CPE workshops, seminars and/or events
Develop online seminars about research topics/methods given by experts in the field
Organisation of high-level research training classes (also at Ph.D. and post-doc level)
Support collaboration through networks and mentoring A specific forum to help people who are interested to meet each other
Establish a network and bringing together persons with a similar research interest(s)
Opportunities for collaboration with colleagues having more experience or having 
experience in a complementary field
Facilitate international research cooperation. Make a database of persons and related 
research activities and possibilities to work together in a (pan)-European context
Support through dissemination of research tools Curate a collection of research tools for clinical pharmacy (e.g. questionnaires, scales, 
documentation guides
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supervising, publishing and presenting research to a much 
higher extent than in previous studies [7, 8]. This finding 
is not surprising given the high proportion of academics 
within the study respondents, for whom there would be 
expectations of research activities. There is the potential to 
harness activities of these individuals to augment research 
capacity, aligned to the aim of ESCP. As an international 
organisation, there is an opportunity for ESCP to support 
Table 5  Barriers to research aspirations ESCP members
Themes Subthemes
Insufficient collaboration Limited opportunities to work across country borders
Knowing who to collaborate with
Finding collaborators based in other countries
How to have different pharmacy sectors collaborating together
Lack of knowledge, skills and training Need for training at all stages of research; development of ideas, data management, statis-
tics, obtaining ethical approval, scientific writing and publication
Lack of mentorship to enhance the development of advanced research skills
Lack of expertise to ensure no key methodological flaws
Difficulties in publishing if non-native English speaker
Unsupportive environment in practice Unsupportive environment and lack of opportunities to participate in research
Doing research on a hospital ward or community pharmacy where research is not a priority
Lack of support to take research to the ‘next step’
Difficulty in getting acceptance from international journals due to ‘local data’
How to deal with breaks in the scientific career (e.g. due to family)
Insufficient time Due to current workload
Too much work
How to maintain work life balance
Limited resources and funding opportunities Not knowing where to access funding
Identifying collaborators to develop funding applications with
Lack of support for financial planning in writing grant applications
Table 6  Expectations from ESCP
Themes Subthemes
Mentorship Early career expressed need for a mentor to provide support at all stages of the research process
Could provide medium for mentoring support
Collaboration Desire to collaborate internationally
Promoted and supported by ESCP via encouraging international communication between 
researchers working in similar areas
Support links between main research centres and possible exchange programmes Discussion 
forums to connect researchers/collaborators
Promote research activities of ESCP members
Could integrate research into the special interest groups
Education Desire for related tutorials or guidelines for research activities
Organization of intensive courses by ESCP to make researchers more competent methodologically
Validated short education programs on research methodology for applying in different countries
Funding To promote awareness of funding opportunities
Collate funding opportunities, e.g. young researchers
Support to encourage/develop applications for the funding calls
Develop suite of templates e.g. proposal, consent, information leaflet
Publication Practical sessions on writing for publication
Support to write manuscripts that are more likely to be accepted in scientific journals
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multicentre research to optimise the impact on patients, 
practitioners, organisations and society.
The summary scores for research interest were significantly 
higher than for experience confidence, as has been found in 
other studies of pharmacists [7, 8] and other health profession-
als [18–22]. However, the actual scores for ESCP respondents 
were much higher than in other studies. For example, a recent 
study of pharmacists in Scotland gave median summary scores 
of 50, 38.5 and 42 using the same scales for interest, experi-
ence and confidence respectively compared to 68, 62 and 64 in 
this study [8]. Again, these differences are likely to be attrib-
uted to the differences in characteristics of the participants on 
the studies.
The scores for the three PCA items were also higher than 
for the same items in the study in Scotland [8]. For the ‘sup-
port and opportunities to be involved in research’, respondents 
were very positive in terms of their research environment, and 
the support from the organisation and others. These responses 
may also reflect the academic setting of many respondents. 
The most negative responses were around time and resources 
for research, which are similar findings to many other studies 
[7, 8]. These issues were also reflected in the themes identified 
from the content analysis of open comments and the discus-
sion groups. The responses for the ‘motivation for and out-
comes of involvement in research’ were particularly positive, 
with respondents in agreement with the impact of research 
on patients, practitioners, organisations and themselves. For 
the ‘individual roles and characteristics around involvement 
in research’, there were positive responses around items of 
confidence, competence and enthusiasm. There are therefore 
many enablers to ESCP members being involved in research.
TDF domains identified as barriers to research can be 
used to aid the development of behaviour change interven-
tions, defined as ‘coordinated sets of activities designed 
to change specified behaviour patterns’ [23, 24]. These 
interventions consist of interacting components known as 
‘behaviour change techniques’ (BCTs), which are ‘observ-
able and replicable components designed to change behav-
iour’ [23, 24]. While the lowest scoring items of time and 
resources map to the TDF domain of ‘environmental context 
and resources’, the BCTs relate more to aspects of culture 
and require intervention at the organisational, leadership and 
management levels. Even though ESCP is not the employing 
organisation for the members, there is opportunity to have 
an influence, as identified in the qualitative element of the 
study.
Future research can centre around ESCP developing 
mechanisms to support these aspects followed by evaluation 
of quantitative (e.g. research activity and output) and quali-
tative (e.g. members’ perspectives) outcomes. In addition, 
there may be merit in focusing on those from non-academic 
settings.
Conclusion
ESCP participants in this study were highly research active, 
interested, experienced, confident and positive regarding 
research conduct and outcomes. There is an opportunity for 
ESCP to harness these activities, aligned to the ESCP aim, 
and provide support in the form of mentoring, education and 
training, and facilitating research collaboration.
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